Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

The Efficacy and Safety of Bisphosphonates for Osteoporosis in Women Older Than 65 Years: A Meta-Analysis

Author(s): Qin Fan and Junjie Wang*

Volume 26, Issue 32, 2020

Page: [4022 - 4030] Pages: 9

DOI: 10.2174/1381612826666200423092602

Price: $65

Abstract

Background: Osteoporosis presents a major threat to the health of women older than 65 years. Bisphosphonates (BPs) are now the principal class of medications for osteoporosis.

Objective: To evaluate the efficacy and safety of BPs in women older than 65 years.

Methods: A comprehensive search in the PubMed, EMBASE, Web of Science and Cochrane Central databases was undertaken for randomized controlled trials (RCTs) on the efficacy and safety of BPs in women older than 65 years. The primary outcome measures were the change in bone mass density (BMD), serum bone turnover marker levels, fracture rate and the adverse effect (AE) rate. The final search was performed in August 2019.

Results: Seven RCTs were included. A total of 23287 patients met the inclusion criteria. BPs significantly increased the BMD of the posteroanterior (PA) spine, lateral spine and femoral neck, and reduced the fracture, vertebrate fracture and hip fracture rates in women older than 65 years. In addition, BPs increased the risks for pyrexia, myalgia, arthralgia, headache and influenza-like symptoms and had no statistical effect on any AEs, any serious AEs, discontinuation due to AEs, oesophagitis, any upper gastrointestinal adverse event, atrial fibrillation and myocardial infarction occurrence in women older than 65 years. Finally, intravenous BPs reduced hip fracture risk but increased AEs in women older than 65 years.

Conclusion: Despite the fact that AEs significantly increased after drug delivery, BPs are highly effective and safe for managing osteoporosis in women older than 65 years. Zoledronic acid caused an increased rate of AEs in women older than 65 years, but these AEs seemed to be mild to moderate. In addition, the hip fracture rate in women older than 80 years old treated with BPs was different than that in the other included patients. Therefore, doctors may prescribe BPs for women older than 65 years in order to increase BMD, and AEs and hip fractures in women older than 80 years should be given attention.

Keywords: Osteoporosis, old women, bone mass density, bisphosphonates, meta-analysis, randomized controlled trials.

« Previous
[1]
Consensus development conference. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94(6): 646-50.
[http://dx.doi.org/10.1016/0002-9343(93)90218-E] [PMID: 8506892]
[2]
Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8: 136.
[http://dx.doi.org/10.1007/s11657-013-0136-1] [PMID: 24113837]
[3]
Kohl HW III, Craig CL, Lambert EV, et al. Lancet physical activity series working group. The pandemic of physical inactivity: global action for public health. Lancet 2012; 380(9838): 294-305.
[http://dx.doi.org/10.1016/S0140-6736(12)60898-8] [PMID: 22818941]
[4]
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75(4): 1092-8.
[PMID: 1400877]
[5]
Greenspan SL, Perera S, Nace D, et al. FRAX or fiction: Determining optimal screening strategies for treatment of osteoporosis in residents in long-term care facilities. J Am Geriatr Soc 2012; 60(4): 684-90.
[http://dx.doi.org/10.1111/j.1532-5415.2011.03884.x] [PMID: 22316237]
[6]
Chandler JM, Zimmerman SI, Girman CJ, et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 2000; 284(8): 972-7.
[http://dx.doi.org/10.1001/jama.284.8.972] [PMID: 10944642]
[7]
Zimmerman S, Chandler JM, Hawkes W, et al. Effect of fracture on the health care use of nursing home residents. Arch Intern Med 2002; 162(13): 1502-8.
[http://dx.doi.org/10.1001/archinte.162.13.1502] [PMID: 12090887]
[8]
Lyles KW, Schenck AP, Colón-Emeric CS. Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents. Osteoporos Int 2008; 19(8): 1225-33.
[http://dx.doi.org/10.1007/s00198-008-0569-3] [PMID: 18301857]
[9]
Office of the Surgeon G. Reports of the surgeon general bone health and osteoporosis: a report of the Surgeon General Rockville (MD). US: Office of the Surgeon General 2004..
[10]
Neuman MD, Silber JH, Magaziner JS, Passarella MA, Mehta S, Werner RM. Survival and functional outcomes after hip fracture among nursing home residents. JAMA Intern Med 2014; 174(8): 1273-80.
[http://dx.doi.org/10.1001/jamainternmed.2014.2362] [PMID: 25055155]
[11]
Campanha-Versiani L, Pereira DAG, Ribeiro-Samora GA, et al. The effect of a muscle weight-bearing and aerobic exercise program on the body composition, muscular strength, biochemical markers, and bone mass of obese patients who have undergone gastric bypass surgery. Obes Surg 2017; 27(8): 2129-37.
[12]
Gómez-Cabello A, Ara I. González Agüero. Effects of training on bone mass in older adults: A systematic review. Sports Med 2012; 42(4): 301-25.
[13]
Kanis JA, Cooper C, Rizzoli R, Reginster JY. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 2019; 104(3): 235-8.
[http://dx.doi.org/10.1007/s00223-018-00512-x] [PMID: 30796490]
[14]
Duque G. Osteoporosis in older persons: Current pharmacotherapy and future directions. Expert Opin Pharmacother 2013; 14(14): 1949-58.
[http://dx.doi.org/10.1517/14656566.2013.822861] [PMID: 23885760]
[15]
Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012; 97(6): 1871-80.
[http://dx.doi.org/10.1210/jc.2011-3060] [PMID: 22466336]
[16]
S N. SL G. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 2019; 30(4): 705-20.
[17]
Naylor KE, Bradburn M, Paggiosi MA, et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 2018; 29(6): 1407-17.
[http://dx.doi.org/10.1007/s00198-018-4460-6] [PMID: 29525970]
[18]
Liang B-C, Shi Z-Y, Wang B, et al. Intravenous zoledronic acid 5 mg on bone turnover markers and bone mineral density in east china subjects with newly diagnosed osteoporosis: A 24-month clinical study. Orthop Surg 2017; 9(1): 103-9.
[http://dx.doi.org/10.1111/os.12307] [PMID: 28276638]
[19]
Stovall DW, Beard MK, Barbier S, Chen E, Rosenberg E, de Papp AE. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women. J Womens Health (Larchmt) 2010; 19(3): 491-7.
[http://dx.doi.org/10.1089/jwh.2009.1438] [PMID: 20141367]
[20]
Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015; 175(6): 913-21.
[http://dx.doi.org/10.1001/jamainternmed.2015.0747] [PMID: 25867538]
[21]
Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 2018; 379(25): 2407-16.
[http://dx.doi.org/10.1056/NEJMoa1808082] [PMID: 30575489]
[22]
McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007; 22(1): 135-41.
[http://dx.doi.org/10.1359/jbmr.061008] [PMID: 17042717]
[23]
Black DM, Delmas PD, Eastell R, et al. HORIZON pivotal fracture trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22.
[http://dx.doi.org/10.1056/NEJMoa067312] [PMID: 17476007]
[24]
Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13(9): 1431-8.
[http://dx.doi.org/10.1359/jbmr.1998.13.9.1431] [PMID: 9738515]
[25]
McClung MR, Geusens P, Miller PD, et al. Hip intervention program study group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344(5): 333-40.
[http://dx.doi.org/10.1056/NEJM200102013440503] [PMID: 11172164]
[26]
Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 136(10): 742-6.
[http://dx.doi.org/10.7326/0003-4819-136-10-200205210-00009] [PMID: 12020142]
[27]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[28]
Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151(10): 2026-32.
[http://dx.doi.org/10.1001/archinte.1991.00400100100017] [PMID: 1929691]
[29]
Adams JE. Quantitative computed tomography. Eur J Radiol 2009; 71(3): 415-24.
[http://dx.doi.org/10.1016/j.ejrad.2009.04.074] [PMID: 19682815]
[30]
Johnell O, Gullberg B, Allander E, Kanis JA. MEDOS Study Group. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int 1992; 2(6): 298-302.
[http://dx.doi.org/10.1007/BF01623186] [PMID: 1421798]
[31]
Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis-reply to Pazianas and Abrahamsen. Osteoporos Int 2014; 25(11): 2671-2.
[http://dx.doi.org/10.1007/s00198-014-2789-z] [PMID: 25035138]
[32]
Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2(1): 7-14.
[http://dx.doi.org/10.1200/jop.2006.2.1.7] [PMID: 20871729]
[33]
Barrionuevo PKE, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 2019; 104(5): 1623-30.
[http://dx.doi.org/10.1210/jc.2019-00192]
[34]
Frediani B, Baraldi E, Cremonesi G. Effect of clodronate treatment on risk of fracture: A systematic review and meta-analysis. Calcif Tissue Int 2014; 95(4): 295-307.
[http://dx.doi.org/10.1007/s00223-014-9903-2] [PMID: 25113241]

Rights & Permissions Print Cite
Article Metrics
43
1
© 2024 Bentham Science Publishers | Privacy Policy